Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
8.79
USD
+1.74%
+5.40%
+56.96%
SIGA Technologies, Inc.'s Equity Buyback announced on August 5, 2021, has expired with 4,152,118 shares, representing 5.69% for $28.49 million.
The company expired its plan on December 31, 2023.
SIGA Technologies to Drive International Promotion for Oral TPOXX in Amended Deal With Meridian Medical
Apr. 01
MT
SIGA Technologies, Inc. Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX
Apr. 01
CI
SIGA Technologies, Inc. Announces the Appointment of Larry Miller as General Counsel
Mar. 25
CI
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High
Mar. 13
DJ
Tranche Update on SIGA Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2021.
Mar. 12
CI
SIGA Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
Transcript : SIGA Technologies, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Mar. 12
Sector Update: Health Care Stocks Rise Late Afternoon
Mar. 12
MT
SIGA Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
SIGA Technologies Share Rise After Special Cash Dividend Announcement
Mar. 12
MT
Siga Technologies, Inc. Declares A Special Cash Dividend, Payable on April 11, 2024
Mar. 12
CI
SIGA Technologies Names Diem Nguyen as Chief Executive
Jan. 22
MT
Siga Technologies, Inc. Appoints Diem Nguyen to the Board of Directors
Jan. 22
CI
SIGA Technologies, Inc. Announces CEO Changes
Jan. 22
CI
SIGA Technologies, Inc.'s Equity Buyback announced on August 5, 2021, has expired with 4,152,118 shares, representing 5.69% for $28.49 million.
Dec. 30
CI
Stigma, regulatory barriers delay mpox response in country that needs it most
Dec. 05
RE
SIGA Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Earnings Flash (SIGA) SIGA TECHNOLOGIES Posts Q3 Revenue $9.2M
Nov. 07
MT
Transcript : SIGA Technologies, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Tranche Update on SIGA Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2021.
Nov. 07
CI
SIGA Says European Commission Forms Procurement Mechanism For Oral TPOXX
23-10-23
MT
SIGA Technologies, Inc. Appoints Jay K. Varma as EVP and Chief Medical Officer
23-09-06
CI
SIGA Technologies Names Jay Varma as Chief Medical Officer
23-09-06
MT
SIGA Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-08
CI
Transcript : SIGA Technologies, Inc., Q2 2023 Earnings Call, Aug 08, 2023
23-08-08
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
More about the company
1st Jan change
Capi.
+56.96% 625M +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1